Parkman Healthcare Partners LLC Decreases Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Parkman Healthcare Partners LLC decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 29.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 126,471 shares of the biopharmaceutical company’s stock after selling 53,849 shares during the quarter. Parkman Healthcare Partners LLC owned about 0.08% of TG Therapeutics worth $2,958,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of TGTX. HighTower Advisors LLC boosted its stake in TG Therapeutics by 19.6% during the third quarter. HighTower Advisors LLC now owns 12,526 shares of the biopharmaceutical company’s stock worth $294,000 after buying an additional 2,053 shares during the last quarter. PFM Health Sciences LP purchased a new stake in shares of TG Therapeutics in the third quarter valued at about $5,459,000. PDT Partners LLC acquired a new stake in TG Therapeutics during the third quarter worth about $1,419,000. Captrust Financial Advisors raised its stake in TG Therapeutics by 21.1% during the third quarter. Captrust Financial Advisors now owns 30,327 shares of the biopharmaceutical company’s stock worth $709,000 after purchasing an additional 5,279 shares during the period. Finally, Public Sector Pension Investment Board purchased a new stake in shares of TG Therapeutics in the 3rd quarter valued at approximately $6,619,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now directly owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TGTX shares. HC Wainwright increased their price objective on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. TD Cowen began coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. B. Riley lifted their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. upped their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. Finally, The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Trading Down 4.8 %

Shares of TGTX opened at $33.39 on Wednesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a 1-year low of $12.84 and a 1-year high of $36.84. The firm has a 50 day simple moving average of $26.82 and a 200-day simple moving average of $22.44. The stock has a market cap of $5.20 billion, a price-to-earnings ratio of -333.87 and a beta of 2.25.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same period in the prior year, the company earned $0.73 EPS. The company’s revenue was down 49.4% compared to the same quarter last year. Equities analysts forecast that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.